Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Guido Ghilardi et al.|Nature Medicine|2022Cited by 308
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Marco Ruella, Yong Gu Lee et al.|Cancer Discovery|2020Cited by 297
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R. Litzow, Martin S. Tallman, Zhuoxin Sun et al.|New England Journal of Medicine|2024Cited by 213
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119